NeedleTech increases production area with new 73,000-square foot manufacturing facility

U.S. Congressman James McGovern, State Representative Elizabeth Poirier and local dignitaries joined Theragenics Corporation (NYSE:TGX) executives in ribbon cutting ceremonies on October 15 for a new 73,000-square foot manufacturing facility for the company's subsidiary, NeedleTech Products. The new facility increases NeedleTech's production area by 30% or 20,000 square feet, allowing the company to consolidate two separate older facilities into one location. The new building will allow NeedleTech to expand operations, increase R&D and offer more services to its customers.

“Our investment in this facility demonstrates Theragenics' commitment to support growth in our surgical products business. Our specialty needle business was severely cramped for space, and the new quarters increase capacity, streamline operations, and provide NeedleTech with the capability to offer more development and fulfillment options to customers.”

Joseph Plante, President of NeedleTech commented, "The new facility allows us to provide faster turn-around and increases our capabilities, especially in the areas of metal fabrication, overmolding, clean room assembly and packaging and quick-turn prototyping. Just as importantly, our dedicated staff is now even better equipped to provide superior service to our customers."

M. Christine Jacobs, Chairman and CEO of Theragenics Corporation commented, "Our investment in this facility demonstrates Theragenics' commitment to support growth in our surgical products business. Our specialty needle business was severely cramped for space, and the new quarters increase capacity, streamline operations, and provide NeedleTech with the capability to offer more development and fulfillment options to customers."

SOURCE Theragenics Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
VANCE trial marks milestone in t cell therapy for solid tumors